Cargando…

Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study

BACKGROUND: A fixed-dose combination (FDC) of amlodipine and losartan has been used to reduce blood pressure in patients whose hypertension is not sufficiently controlled with either drug alone. The aim of this study was to evaluate the pharmacokinetic (PK) characteristics and tolerability of an FDC...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, YoonJung, Lee, SeungHwan, Cho, Sang-Min, Kang, Won-Ho, Nam, Kyu-Yeol, Jang, In-Jin, Yu, Kyung-Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036556/
https://www.ncbi.nlm.nih.gov/pubmed/27703330
http://dx.doi.org/10.2147/DDDT.S113891
_version_ 1782455575523622912
author Choi, YoonJung
Lee, SeungHwan
Cho, Sang-Min
Kang, Won-Ho
Nam, Kyu-Yeol
Jang, In-Jin
Yu, Kyung-Sang
author_facet Choi, YoonJung
Lee, SeungHwan
Cho, Sang-Min
Kang, Won-Ho
Nam, Kyu-Yeol
Jang, In-Jin
Yu, Kyung-Sang
author_sort Choi, YoonJung
collection PubMed
description BACKGROUND: A fixed-dose combination (FDC) of amlodipine and losartan has been used to reduce blood pressure in patients whose hypertension is not sufficiently controlled with either drug alone. The aim of this study was to evaluate the pharmacokinetic (PK) characteristics and tolerability of an FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium compared to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium in healthy subjects. SUBJECTS AND METHODS: A randomized, open-label, single-dose, two-period, two-sequence crossover study was conducted on 46 healthy male subjects. Blood concentrations were measured by liquid chromatography–tandem mass spectrometry. Blood samples were collected up to 144 hours post dose for each period. PK parameters were calculated in each treatment group using a noncompartmental method. The 90% confidence intervals (CIs) of the geometric mean ratios of the two treatments for the maximum plasma concentration (C(max)) and the area under the concentration curve from time zero to the last quantifiable time point (AUC(0–t)) were estimated. Tolerability assessments were performed for all subjects who received the drug at least once. RESULTS: The PK profiles of the two treatments were similar. For amlodipine, the geometric mean ratios (90% CIs) of amlodipine besylate to amlodipine camsylate for the C(max) and AUC(0–t) were 0.98 (0.94−1.01) and 0.97 (0.93−1.01), respectively. The corresponding values for losartan were 0.91 (0.81−1.02) and 1.05 (0.98−1.12), respectively. The incidence of adverse events was not significantly different between the two treatments, and both were well tolerated. CONCLUSION: An FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium produced similar results to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium treatment with respect to the PK parameters of amlodipine and losartan based on C(max) and AUC(0–t) values. The amlodipine besylate/losartan potassium combination was well tolerated by healthy male subjects.
format Online
Article
Text
id pubmed-5036556
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50365562016-10-04 Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study Choi, YoonJung Lee, SeungHwan Cho, Sang-Min Kang, Won-Ho Nam, Kyu-Yeol Jang, In-Jin Yu, Kyung-Sang Drug Des Devel Ther Original Research BACKGROUND: A fixed-dose combination (FDC) of amlodipine and losartan has been used to reduce blood pressure in patients whose hypertension is not sufficiently controlled with either drug alone. The aim of this study was to evaluate the pharmacokinetic (PK) characteristics and tolerability of an FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium compared to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium in healthy subjects. SUBJECTS AND METHODS: A randomized, open-label, single-dose, two-period, two-sequence crossover study was conducted on 46 healthy male subjects. Blood concentrations were measured by liquid chromatography–tandem mass spectrometry. Blood samples were collected up to 144 hours post dose for each period. PK parameters were calculated in each treatment group using a noncompartmental method. The 90% confidence intervals (CIs) of the geometric mean ratios of the two treatments for the maximum plasma concentration (C(max)) and the area under the concentration curve from time zero to the last quantifiable time point (AUC(0–t)) were estimated. Tolerability assessments were performed for all subjects who received the drug at least once. RESULTS: The PK profiles of the two treatments were similar. For amlodipine, the geometric mean ratios (90% CIs) of amlodipine besylate to amlodipine camsylate for the C(max) and AUC(0–t) were 0.98 (0.94−1.01) and 0.97 (0.93−1.01), respectively. The corresponding values for losartan were 0.91 (0.81−1.02) and 1.05 (0.98−1.12), respectively. The incidence of adverse events was not significantly different between the two treatments, and both were well tolerated. CONCLUSION: An FDC of 6.94 mg amlodipine besylate (5 mg as amlodipine)/50 mg losartan potassium produced similar results to an FDC of 5 mg amlodipine camsylate/50 mg losartan potassium treatment with respect to the PK parameters of amlodipine and losartan based on C(max) and AUC(0–t) values. The amlodipine besylate/losartan potassium combination was well tolerated by healthy male subjects. Dove Medical Press 2016-09-20 /pmc/articles/PMC5036556/ /pubmed/27703330 http://dx.doi.org/10.2147/DDDT.S113891 Text en © 2016 Choi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Choi, YoonJung
Lee, SeungHwan
Cho, Sang-Min
Kang, Won-Ho
Nam, Kyu-Yeol
Jang, In-Jin
Yu, Kyung-Sang
Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title_full Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title_fullStr Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title_full_unstemmed Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title_short Comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
title_sort comparisons of the pharmacokinetics and tolerability of fixed-dose combinations of amlodipine besylate/losartan and amlodipine camsylate/losartan in healthy subjects: a randomized, open-label, single-dose, two-period, two-sequence crossover study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036556/
https://www.ncbi.nlm.nih.gov/pubmed/27703330
http://dx.doi.org/10.2147/DDDT.S113891
work_keys_str_mv AT choiyoonjung comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT leeseunghwan comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT chosangmin comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT kangwonho comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT namkyuyeol comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT janginjin comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy
AT yukyungsang comparisonsofthepharmacokineticsandtolerabilityoffixeddosecombinationsofamlodipinebesylatelosartanandamlodipinecamsylatelosartaninhealthysubjectsarandomizedopenlabelsingledosetwoperiodtwosequencecrossoverstudy